NCT00002321View on ClinicalTrials.gov

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Cytomegalovirus RetinitisHIV Infections

Interventions

DRUG

Aldesleukin

Trial Locations (1)

43699

Med College of Ohio, Toledo

Sponsors

Lead Sponsor

Chiron Corporation

All Listed Sponsors

lead

Chiron Corporation

INDUSTRY

NCT00002321 - A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis | Biotech Hunter | Biotech Hunter